Visit
Robert Hadden, BM BCh, FRCP, PhD, King’s College Hospital, London, UK, discusses the predictive markers of patients likely to experience neurotoxicity symptoms, and how such symptoms may arise. This interview took place at the CAR-T Cell Therapy and the ICU meeting in London, UK, which was organized by EuroCARTForce.
VJHemOnc is intended for Healthcare Professionals onlyBy choosing to continue, you are confirming that you are a healthcare professional
VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.
